The Types axis of HCG Pregnancy Detection Kits market taxonomy classifies products according to the underlying assay technology, principally lateral flow immunoassay (LFIA), enzyme‑linked immunosorbent assay (ELISA), and emerging digital immunoassay platforms. LFIA kits dominate the volume‑based share, accounting for roughly 70 % of shipments, because they deliver results within five minutes, require no instrumentation, and align with the home‑use application. ELISA kits, typically employed in clinical laboratories, represent about 25 % of market value; although slower (30–60 minutes) and instrument‑dependent, they provide quantitative hCG concentrations that support clinical decision‑making and longitudinal monitoring. Digital immunoassays, incorporating smartphone‑linked readers or microfluidic chips, occupy the remaining 5 % of the market but exhibit the highest average selling price, reflecting their enhanced sensitivity (detecting <5 mIU/mL) and data‑integration capabilities. The relative contribution of each type is therefore a function of assay speed, required analytical performance, and end‑user setting. This segmentation underscores a clear hierarchy: LFIA sustains mass‑market demand, ELISA anchors high‑value clinical revenue, and digital formats signal a niche yet fast‑growing innovation frontier within the HCG Pregnancy Detection Kits segmentation.
